Development and Evaluation of Novel Olmesartan Cocrystals: A Strategy for Improving Aqueous Solubility and Dissolution Rate
International Journal of Drug Delivery Technology · 25.04.2026 · 16 (22s)
DOI: 10.25258/ijddt.16.22s.46 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 25.04.2026. Verfasst von Mahesh D. Pawar und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Objective
The present study aimed to enhance the solubility, dissolution rate and oral bioavailability of Olmesartan Medoxomil, a poorly water-soluble antihypertensive agent, through the development of pharmaceutical co-crystals using salicylic acid and benzoic acid as co-formers.
Methods
Co-crystals of Olmesartan were prepared in 1:1 and 1:2 molar ratios using dry grinding (DG), liquid-assisted grinding (LAG) and solvent evaporation (SE) methods. The prepared co-crystals were evaluated for saturation solubility, Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), Scanning Electron Microscopy (SEM) and in-vitro dissolution study.
Results
All co-crystal formulations showed a significant improvement in solubility and dissolution compared to pure Olmesartan. Among them, the optimized formulation OC-S2-SE (Olmesartan : Salicylic acid, 1:2, solvent evaporation) exhibited the highest saturation solubility (0.092 ± 0.012 mg/mL) and drug release (97.86% in 60 minutes). FTIR and DSC confirmed co-crystal formation through characteristic peak shifts and the emergence of a new thermal event at 115.96 °C. SEM analysis revealed a distinct change in surface morphology with uniform and compact crystal aggregates. Batch OC-S2-SE (Olmesartan:Salicylic acid, 1:2) emerged as the optimized formulation, offering nearly four-fold improvement in drug release compared to pure drug.
Conclusion
Co-crystallization of Olmesartan with salicylic acid, especially via solvent evaporation, is a promising strategy to overcome its solubility and bioavailability limitations. The study validates the potential of pharmaceutical cocrystals to improve the therapeutic efficacy of poorly water-soluble drugs
Zitieren
APA
Pawar, M. D., & Singh, S. (2026). Development and Evaluation of Novel Olmesartan Cocrystals: A Strategy for Improving Aqueous Solubility and Dissolution Rate. International Journal of Drug Delivery Technology, 16(22s). https://doi.org/10.25258/ijddt.16.22s.46
Vancouver
Pawar MD, Singh S. Development and Evaluation of Novel Olmesartan Cocrystals: A Strategy for Improving Aqueous Solubility and Dissolution Rate. International Journal of Drug Delivery Technology. 2026;16(22s). doi:10.25258/ijddt.16.22s.46
BibTeX
@article{Pawar2026,
author = {Pawar, Mahesh D. and Singh, Sunder},
title = {Development and Evaluation of Novel Olmesartan Cocrystals: A Strategy for Improving Aqueous Solubility and Dissolution Rate},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {22s},
doi = {10.25258/ijddt.16.22s.46}
}
EUVIMED